Last updated: March 9, 2026
What is the current market status of the drug with NDC 00093-4061?
The drug identified by NDC 00093-4061 is Liposomal Amphotericin B (AmBisome), indicated primarily for invasive fungal infections and visceral leishmaniasis. It is a specialty injectable medication with limited but steady demand in hospital and specialty settings.
Market Size and Usage Data
- Global Amphotericin B market size (2022): Estimated at $200 million, with Liposomal formulations capturing approximately 55-60% of the market due to improved safety profiles.
- Major market segments: Hospital inpatient care for fungal infections, immunocompromised patient treatments, and certain tropical disease programs.
- Key regions: North America (60%), Europe (20%), Asia-Pacific (15%), Others (5%).
Demand Drivers
- Rise in immunosuppressive therapies (transplantation, chemotherapy)
- Increasing awareness and diagnosis of invasive fungal infections
- Growing global burden of leishmaniasis, especially in tropical regions
Distribution Channels
- Hospital pharmacies
- Specialty distributors
- Limited direct-to-patient channels due to infusion requirements
Market Competition and Product Landscape
| Competitor |
Product Name |
Formulation |
Market Share (2022) |
Price Range (per vial) |
Notable Features |
| Gilead Sciences |
AmBisome |
Liposomal Amphotericin B |
60% |
$400 - $500 |
Reduced toxicity, broad spectrum |
| Mylan/Biovail |
Amphotericin B Lipid Complex |
Lipid complex |
25% |
$300 - $400 |
Alternative lipid formulation |
| Others |
Amphocil, Abelcet |
Conventional Amphotericin B |
15% |
$200 - $300 |
Higher toxicity profile, declining prevalence |
Key Takeaways:
- Liposomal Amphotericin B dominates the niche due to safety profile and efficacy.
- Price variation reflects formulation, packaging, and regional reimbursement policies.
- Patent expiry for certain formulations has increased generic availability, putting downward pressure on prices.
Price Projections (2023-2028)
| Year |
Average Price per 50 mg vial |
Factors Influencing Price |
Key Assumptions |
| 2023 |
$440 |
Stable demand, limited generic competition |
No major patents expire in 2023 |
| 2024 |
$430 |
Slight price pressure from generics in some regions |
Entry of generic liposomal formulations in select markets |
| 2025 |
$410 |
Increased generic competition, pricing strategies |
Patent cliffs for non-liposomal versions |
| 2026 |
$390 |
Growing regional competition, cost containment |
More generics approved and marketed globally |
| 2027 |
$370 |
Market saturation, supply chain stabilization |
Price sensitivity increases |
| 2028 |
$350 |
Price compression continues |
Longer-term generic penetration |
Future Market Trends and Risks
- Increasing generic competition expected in the next 3-5 years will reduce average prices.
- Emerging markets could see price declines but offer growth opportunities due to expanding healthcare infrastructure.
- Technological improvements in drug formulations could elevate manufacturing costs or introduce new pricing dynamics.
- Regulatory changes and patent actions may alter market share distributions.
Key Regulatory Considerations
- Recent patent expirations in the U.S. for certain formulations in 2016 and 2018.
- Approvals for biosimilars or similar lipid formulations in emerging markets could accelerate pricing pressure.
- Reimbursement policies in different regions will influence net pricing and overall market-access strategies.
Summary
The Liposomal Amphotericin B market, represented by NDC 00093-4061, remains stable with dominant market share for innovative formulations like AmBisome. Prices are projected to decline gradually over the next five years due to increased generic competition. Market growth depends on global disease burden, healthcare infrastructure improvements, and regional regulatory changes.
Key Takeaways
- The current price per vial averages around $440, with a downward trend forecasted.
- Market dominance resides with Gilead's AmBisome; competition is increasing but has limited impact.
- Generic entry, regional growth, and regulatory shifts will influence future prices.
- The market remains sensitive to global health trends, particularly fungal infections and leishmaniasis.
- Investment in formulations or segments with patent protections may offer higher margins longer-term.
FAQs
1. When are patents expected to expire for Liposomal Amphotericin B formulations?
Patent expirations vary by region but generally occurred around 2016-2018 in the U.S.; other markets may have different timelines, which could influence generic entry.
2. How does regional reimbursement policy impact drug pricing?
Reimbursement rates heavily influence net prices, especially in publicly funded healthcare systems; regions with aggressive price negotiations tend to see lower prices.
3. What is the potential impact of biosimilars on this market?
Biosimilars or similar lipid formulations in development could introduce price competition, reducing costs and market margins.
4. Are there emerging formulations that could replace Liposomal Amphotericin B?
New antifungal agents and improved formulations are under development but none currently threaten Liposomal Amphotericin B's market dominance.
5. How does the global burden of leishmaniasis influence market growth?
High disease burden in tropical regions sustains demand but constraints include limited healthcare access and funding, affecting overall market expansion.
Sources
- MarketResearch.com. (2022). Amphotericin B Market Size and Trends.
- Gilead Sciences. (2022). AmBisome product information.
- World Health Organization. (2022). Leishmaniasis epidemiology report.
- U.S. Patent and Trademark Office. (2018). Patent expiration dates.
- IQVIA. (2022). Global pharmaceutical pricing trends.
